Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

Accreditation for Cardiovascular Excellence achieves record-breaking cardiac cath lab applications

Rounding out a very successful year, Accreditation for Cardiovascular Excellence (ACE) reports they have reached record-breaking numbers of accreditation applications for cardiac cath labs in 2013. “Accreditation applications have more than doubled since 2012,” said Mary Heisler, RN, BA, ACE Executive Director. “More labs are realizing the importance of accountable metrics and know it’s time to get started on the quality journey with ACE.”

First-in-man study shows feasibility of bioresorbable scaffold

Researchers for the DESolve study recommended testing the latest iteration of the device in a larger group of patients, based on results of a first-in-man-study published in the December issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

Review challenges benefit of PCI plus medical therapy

A combination of PCI and medical therapy did not lead to better outcomes in patients with stable coronary artery disease and MI compared with medical therapy alone, a review published online Dec. 2 in JAMA Internal Medicine found.

CABG outshines PCI for long-term risk reduction

CABG offers a greater long-term benefit to patients with multivessel disease than PCI does, regardless of diabetes status, according to a meta-analysis published online Dec. 2 in JAMA Internal Medicine. CABG reduced the risk of death or MI but showed a trend toward excess strokes.

Thumbnail

FDA approves Promus Premier stent system

The FDA has given Boston Scientific the green light to market its next-generation durable polymer drug-eluting stent in the U.S.

Devices may be safer than manual closure during PCI

Using vascular closure devices during PCI may be safer than manual closure, according to a study published online Nov. 18 in Annals of Internal Medicine. The devices were associated with fewer vascular complications and a reduced need for transfusions in patients undergoing transfemoral PCI.

AHA: Varespladib raises heart attack risk in ACS patients

Varespladib significantly increased heart attack risk in patients with acute coronary syndrome (ACS) in a trial that terminated early due to futility and potential harm. The study findings were published online Nov. 18 in JAMA and presented simultaneously at the American Heart Association’s scientific session.

American Heart Association council honors Harvard investigator for discovery of new life-saving heart attack treatment

The American Heart Association’s Council on Clinical Cardiology presented its James B. Herrick Award for outstanding achievement in clinical cardiology to Marc Alan Pfeffer, M.D., Ph.D., of Harvard Medical School “for acclaimed research showing how cardiac muscle damage occurs during a heart attack, a discovery that led to new life-saving treatment.”

Displaying 1769 - 1776 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.